Registered title, quoted from ClinicalTrials.gov
Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT04944914, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
Imageological evidence for oligometastatic lesions (metastatic tissue biopsy preferred but not necessary). The number of total metastatic lesions no more than 5 and the number of metastatic lesions within a single organ no more than 3.
Inclusion criterion 4
ECOG performance status of 0 or 1.
Inclusion criterion 5
Active tuberculosis (TB), anti-TB treatment is ongoing or within 1 year prior to screening
Exclusion criterion 11
Has a known history of human immunodeficiency virus (HIV), has hepatitis B surface antigen (HBsAg) positive with hepatitis B virus (HBV) DNA copy number of ≥1000cps/ml or hepatitis C virus (HCV) antibody positive.
Exclusion criterion 13
Pregnancy or lactation.
Exclusion criterion 15
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04944914, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Male or female; 18-70 years of age.
- Primary lesion and regional lymph nodes completed radical radiotherapy 3 months before stereotactic body radiotherapy and diseases well controlled.
- Underwent at least first-line systemic chemotherapy, regardless of regimen and curative effect.
- Imageological evidence for oligometastatic lesions (metastatic tissue biopsy preferred but not necessary). The number of total metastatic lesions no more than 5 and the number of metastatic lesions within a single organ no more than 3.
- ECOG performance status of 0 or 1.
- Stereotactic body radiotherapy applicable for all metastatic lesions according to MDT.
- If metastatic lesions have received local treatment (surgery, radiofrequency ablation, radiotherapy etc.):
- Eligible if treated lesion is well controlled according to imageological examinations, and the lesion does not need stereotactic body radiotherapy.
- If treated lesion is not controlled according to imageological examinations:
- Eligible if the treatment is surgery and that stereotactic body radiotherapy is applicable for the treated lesion.
- Ineligible if the treatment is radiofrequency ablation or radiotherapy.
- Maximum diameter of brain metastatic lesion no more than 3cm.
- Maximum diameter of metastatic lesion (brain excluded) no more than 5cm.
- Maximum diameter of bone metastatic lesion no more than 6cm if attending doctor decides it is safe to apply the treatment.
- Life expectancy more than 12 weeks.
Exclusion Criteria:
- Immunotherapy (PD-1/PD-L1 or CTLA-4 monoclonal antibody) failure.
- CHD no less than grade 2, arrhythmia (QTc interval over 450ms for male and 470ms for female) or cardiac insufficiency.
- History of severe hypersensitivity to any ingredient of PD-1/PD-L1 or other monoclonal antibody.
- chemotherapy (cytotoxic or molecular targeted) within 4 weeks before stereotactic body radiotherapy.
- Imageological evidence for spinal cord compression, or tumor less than 3mm away from spinal cord.
- Patient with brain metastasis who needs decompression surgery.
- Other malignancy or malignant hydrothorax.
- Concurrent known or suspicious autoimmune disease, including dementia and epilepsy.
- Use of large dose corticosteroids within 4 weeks before study drug administration.
- Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids.
- Active tuberculosis (TB), anti-TB treatment is ongoing or within 1 year prior to screening
- Subjects with any active autoimmune disease or history of autoimmune disease, or history of syndrome that requires systemic steroids or immunosuppressive medications, including but not limited to the following: rheumatoid arthritis, pneumonitis, colitis (inflammatory bowel disease), hepatitis, hypophysitis, nephritis, hyperthyroidism, and hypothyroidism, except for subjects with vitiligo or resolved childhood asthma/atopy.
- Has a known history of human immunodeficiency virus (HIV), has hepatitis B surface antigen (HBsAg) positive with hepatitis B virus (HBV) DNA copy number of ≥1000cps/ml or hepatitis C virus (HCV) antibody positive.
- Received any anti-infective vaccine (e.g. influenza vaccine, varicella vaccine, etc.) within 4 weeks prior to enrollment.
- Pregnancy or lactation.
- Other ineligible patients according to attending doctor.
Quoted from ClinicalTrials.gov, NCT04944914, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT04944914, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.